{"id":"iv-gamunex-10","safety":{"commonSideEffects":[{"rate":"20%","effect":"Headache"},{"rate":"15%","effect":"Fatigue"},{"rate":"10%","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL3641219","moleculeType":"Small molecule","molecularWeight":"514.64"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Gamunex 10% is a solution of 10% human immunoglobulin G (IgG) used to treat various immune system disorders.","oneSentence":"Immunomodulation through the administration of intravenous immunoglobulin","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:56:58.238Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Primary immunodeficiency"},{"name":"Chronic inflammatory demyelinating polyneuropathy"},{"name":"Multifocal motor neuropathy"}]},"trialDetails":[{"nctId":"NCT06980480","phase":"PHASE3","title":"A Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma","status":"RECRUITING","sponsor":"Takeda","startDate":"2026-01-14","conditions":"Multiple Myeloma, Secondary Immunodeficiency","enrollment":183},{"nctId":"NCT06859424","phase":"PHASE2","title":"A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation","status":"RECRUITING","sponsor":"Center for International Blood and Marrow Transplant Research","startDate":"2025-07-25","conditions":"AML (Acute Myelogenous Leukemia), Acute Lymphoid Leukemia (ALL), Acute Leukemia (Category)","enrollment":358},{"nctId":"NCT06752356","phase":"PHASE3","title":"A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"RECRUITING","sponsor":"Kedrion S.p.A.","startDate":"2026-04","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":161},{"nctId":"NCT04224558","phase":"PHASE1, PHASE2","title":"Stem Cell Transplantation in Crohn's Disease","status":"RECRUITING","sponsor":"Cedars-Sinai Medical Center","startDate":"2019-11-15","conditions":"Crohn Disease","enrollment":15},{"nctId":"NCT05952804","phase":"PHASE2","title":"IVIG for Infection Prevention After CAR-T-Cell Therapy","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2024-06-10","conditions":"Hematologic Malignancies","enrollment":150},{"nctId":"NCT06954441","phase":"PHASE3","title":"V-IMMUNE: A Novel Immunoglobulin Therapy for Immunodeficiency","status":"RECRUITING","sponsor":"On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.","startDate":"2025-08-15","conditions":"Immunodeficiencies, Primary Immunodeficiencies (PID), Agammaglobulinemia","enrollment":50},{"nctId":"NCT03292861","phase":"PHASE2","title":"The Effect and Safety Profile of Thymoglobulin® in Primary Cardiac Transplant Recipients","status":"ENROLLING_BY_INVITATION","sponsor":"Cedars-Sinai Medical Center","startDate":"2018-09-13","conditions":"Heart Transplantation","enrollment":60},{"nctId":"NCT04083183","phase":"PHASE1, PHASE2","title":"Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2020-06-16","conditions":"Non-Malignant Neoplasm","enrollment":40},{"nctId":"NCT04222023","phase":"PHASE4","title":"Intravenous Immunoglobulins for Prevention of BKV Infection in Kidney Transplant Recipients According to BKV Genotype-specific Neutralizing Antibody Titers at the Day of Transplantation.","status":"COMPLETED","sponsor":"University Hospital, Strasbourg, France","startDate":"2022-08-21","conditions":"Kidney Transplantation","enrollment":359},{"nctId":"NCT01184846","phase":"PHASE3","title":"Study of Efficacy and Safety of Privigen in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy","status":"COMPLETED","sponsor":"CSL Behring","startDate":"2010-11","conditions":"Chronic Inflammatory Demyelinating Polyneuropathy","enrollment":31},{"nctId":"NCT02915263","phase":"PHASE2","title":"The Efficacy Of Intravenous Immunoglobulin Therapy In Treatment Induced Neuropathy Of Diabetes","status":"TERMINATED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2017-09-11","conditions":"Diabetes Complications, Diabetes Mellitus, Diabetic Neuropathies","enrollment":13},{"nctId":"NCT03277313","phase":"PHASE3","title":"Efficacy, Safety, Tolerability, Immunogenicity and Pharmacokinetic Evaluation of HYQVIA in Pediatric PIDD Subjects","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2017-09-25","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":44},{"nctId":"NCT03401073","phase":"PHASE2","title":"IVIg for Small Fiber Neuropathy With Autoantibodies TS-HDS and FGFR3","status":"COMPLETED","sponsor":"Beth Israel Deaconess Medical Center","startDate":"2018-09-01","conditions":"Small Fiber Neuropathy, Idiopathic Peripheral Neuropathy","enrollment":20},{"nctId":"NCT02549170","phase":"PHASE3","title":"A Study of HyQvia and Gammagard Liquid (Kiovig) in Adults With Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-12-15","conditions":"Chronic Inflammatory Demyelinating Polyradiculoneuropathy","enrollment":138},{"nctId":"NCT00033293","phase":"PHASE3","title":"Cyclophosphamide and Prednisone With or Without Immunoglobulin in Treating Abnormal Muscle Movement in Children With Neuroblastoma","status":"COMPLETED","sponsor":"Children's Oncology Group","startDate":"2004-03-15","conditions":"Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma, Regional Neuroblastoma","enrollment":53},{"nctId":"NCT04480424","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of High Dose Intravenous Immune Globulin (IVIG) Plus Standard Medical Treatment (SMT) Versus SMT Alone in Participants in Intensive Care Unit (ICU) With Coronavirus Disease (COVID-19)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2020-09-17","conditions":"COVID-19","enrollment":100},{"nctId":"NCT03065244","phase":"PHASE3","title":"KIDCARE (Kawasaki Disease Comparative Effectiveness Trial)","status":"COMPLETED","sponsor":"University of California, San Diego","startDate":"2017-02-17","conditions":"Mucocutaneous Lymph Node Syndrome","enrollment":105},{"nctId":"NCT01218438","phase":"PHASE2, PHASE3","title":"Phase 2/3 Study of IGSC, 20% in PIDD","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2013-01-28","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":86},{"nctId":"NCT01485796","phase":"PHASE2, PHASE3","title":"Tolerability and Safety of IGI, 10% With rHuPH20 in PIDD","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2011-12-29","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":54},{"nctId":"NCT01175213","phase":"PHASE3","title":"Tolerability and Safety of Immune Globulin Subcutaneous Solution (IGSC) and rHuPH20 in PID","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2010-07-28","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":66},{"nctId":"NCT00814320","phase":"PHASE3","title":"Gammagard Liquid and rHuPH20 in PID","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2008-12-18","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":89},{"nctId":"NCT02129582","phase":"PHASE1","title":"Targeted Marrow Irradiation, Fludarabine Phosphate, and Busulfan Before Donor Progenitor Cell Transplant in Treating Patients With Hematologic Malignancies","status":"COMPLETED","sponsor":"Case Comprehensive Cancer Center","startDate":"2014-11-05","conditions":"Acute Myeloid Leukemia, Hematologic Malignancies, Acute Lymphocytic Leukemia","enrollment":14},{"nctId":"NCT00782106","phase":"PHASE1, PHASE2","title":"Study to Determine the Dose of Recombinant Human Hyaluronidase Needed to Infuse a Full Dose of IGIV Subcutaneously","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2006-12-04","conditions":"Primary Immunodeficiency Diseases (PID)","enrollment":11},{"nctId":"NCT02556775","phase":"","title":"Pregnancy Registry to Collect Long-Term Safety Data From Women Treated With HyQvia","status":"COMPLETED","sponsor":"Baxalta now part of Shire","startDate":"2015-12-04","conditions":"Exposure During Pregnancy","enrollment":16},{"nctId":"NCT02413580","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of IGIV-C in Patients With Myasthenia Gravis Exacerbations","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2015-03","conditions":"Myasthenia Gravis Exacerbations","enrollment":49},{"nctId":"NCT02604810","phase":"PHASE3","title":"Safety and Pharmacokinetics of IGSC 20% in Subjects With Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2016-01","conditions":"Primary Immunodeficiency","enrollment":53},{"nctId":"NCT00115778","phase":"PHASE2","title":"Intravenous Immunoglobulin (IVIG) in Lung Transplantation","status":"COMPLETED","sponsor":"Columbia University","startDate":"2005-06","conditions":"Hypogammaglobulinemia, Lung Transplantation","enrollment":11},{"nctId":"NCT02130817","phase":"PHASE4","title":"Belatacept in Kidney Transplantation of Moderately Sensitized Patients","status":"WITHDRAWN","sponsor":"University of Wisconsin, Madison","startDate":"2014-09-24","conditions":"End Stage Renal Disease, Antibody Mediated Rejection","enrollment":""},{"nctId":"NCT00892112","phase":"PHASE3","title":"Intravenous Immunoglobulin (IVIg) for Parvovirus B19(PVB19) Mediated Cardiomyopathy","status":"COMPLETED","sponsor":"Prothya Biosolutions","startDate":"2009-11","conditions":"Myocardial Diseases, Parvovirus B19, Human","enrollment":50},{"nctId":"NCT00176865","phase":"PHASE2","title":"Stem Cell Transplant for Immunologic or Histiocytic Disorders","status":"COMPLETED","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2002-08","conditions":"Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome","enrollment":19},{"nctId":"NCT00343785","phase":"PHASE2","title":"Cyclophosphamide and Anti-thymocyte Globulin Followed By Methotrexate and Cyclosporine in Preventing Chronic Graft-Versus-Host Disease in Patients With Severe Aplastic Anemia Undergoing Donor Bone Marrow Transplant","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2006-02","conditions":"Aplastic Anemia","enrollment":21},{"nctId":"NCT00000935","phase":"PHASE3","title":"An Evaluation of IV Gamma Globulin As a Method to Improve Kidney Transplant Survival in Patients With End-Stage Renal Disease Who Are Highly Sensitized to Transplant Antigens","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":"End-Stage Renal Disease, Kidney Transplantation","enrollment":100},{"nctId":"NCT00376077","phase":"PHASE3","title":"A Randomized Study of IVIG vs. IVIG With High Dose Methylprednisolone in Childhood ITP.","status":"COMPLETED","sponsor":"The Hospital for Sick Children","startDate":"2005-08","conditions":"Immune Thrombocytopenic Purpura","enrollment":32},{"nctId":"NCT00220727","phase":"PHASE2","title":"Rapid Infusion Of Immune Globulin Intravenous (IGIV) In Patients With ITP","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2003-07","conditions":"Purpura, Thrombocytopenic, Idiopathic","enrollment":8},{"nctId":"NCT00220779","phase":"PHASE2","title":"Immune Globulin Intravenous (IGIV) To Treat Relapsing, Remitting Multiple Sclerosis","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2002-12","conditions":"Multiple Sclerosis, Relapsing-Remitting","enrollment":128},{"nctId":"NCT00220740","phase":"PHASE3","title":"Immune Globulin Intravenous (IGIV) For Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-04","conditions":"Polyradiculoneuropathy, Chronic Inflammatory Demyelinating","enrollment":117},{"nctId":"NCT00220805","phase":"PHASE2","title":"Use of Immune Globulin Intravenous (Human) To Treat Age-Related Macular Degeneration","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2004-01","conditions":"Macular Degeneration","enrollment":96},{"nctId":"NCT00389324","phase":"PHASE2","title":"A Trial of the Pharmacokinetics, Safety, and Tolerability of Subcutaneous Gamunex® in Primary Immunodeficiency","status":"COMPLETED","sponsor":"Grifols Therapeutics LLC","startDate":"2006-11","conditions":"Immunologic Deficiency Syndrome","enrollment":35},{"nctId":"NCT00417573","phase":"PHASE2","title":"Efficacy of IgIv in Patients With IgG Subclass Deficiency and Recurrent Infections","status":"COMPLETED","sponsor":"The Center for Rheumatic Disease, Allergy, & Immunology","startDate":"2004-12","conditions":"IgG Deficiency, Infections","enrollment":10}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"IV Gamunex 10%","genericName":"IV Gamunex 10%","companyName":"The Center for Rheumatic Disease, Allergy, & Immunology","companyId":"the-center-for-rheumatic-disease-allergy-immunology","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Gamunex 10% is a licensed human normal immunoglobulin used for IV infusion to treat various conditions, including diabetes complications and diabetic neuropathies. It is not a small molecule, but rather a type of immunoglobulin.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}